Damora Therapeutics (DMRA) Current Assets (2019 - 2026)

Damora Therapeutics has reported Current Assets for 8 years, with the latest figure at $535.4 million in Q1 2026.

• For the quarter ending Q1 2026, Current Assets rose 3493.34% year-over-year to $535.4 million; the trailing twelve-month figure through Mar 2026 stood at $535.4 million (up 3493.34% YoY), and the FY2025 full-year result was $260.4 million, up 1446.41% from the prior year.
• Current Assets for Q1 2026 stood at $535.4 million, up from $260.4 million in the prior quarter.
• The five-year high for Current Assets was $535.4 million in Q1 2026, with the low at $9.8 million in Q3 2025.
• Historically, Current Assets has averaged $84.6 million across 5 years, with a median of $47.1 million in 2023.
• Annual changes were most pronounced in 2024 — Current Assets sank 54.99% — and 2026, when it surged 3493.34%.
• Damora Therapeutics' Current Assets stood at $63.9 million in 2022, then plunged by 42.45% to $36.8 million in 2023, then tumbled by 54.21% to $16.8 million in 2024, then surged by 1446.41% to $260.4 million in 2025, then jumped by 105.61% to $535.4 million in 2026.
• The last three Current Assets figures came in at $535.4 million (Q1 2026), $260.4 million (Q4 2025), and $9.8 million (Q3 2025), per Business Quant data.